MARKET

CPRX

CPRX

Catalyst Pharmaceuticals Inc
NASDAQ
14.21
+0.11
+0.78%
After Hours: 13.96 -0.25 -1.76% 19:59 11/28 EST
OPEN
14.04
PREV CLOSE
14.10
HIGH
14.28
LOW
13.94
VOLUME
862.73K
TURNOVER
0
52 WEEK HIGH
22.11
52 WEEK LOW
11.09
MARKET CAP
1.51B
P/E (TTM)
27.04
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at CPRX last week (1120-1124)?
Weekly Report · 2d ago
Weekly Report: what happened at CPRX last week (1113-1117)?
Weekly Report · 11/20 10:32
Weekly Report: what happened at CPRX last week (1106-1110)?
Weekly Report · 11/13 10:27
Catalyst Pharma (CPRX) Gets a Buy from Piper Sandler
TipRanks · 11/10 15:16
Catalyst Pharma’s Robust Growth and Innovative Products Drive a Buy Rating: An Analysis of 3Q Performance and Future Prospects
Analyst charles duncan issued a buy rating for catalyst pharma (cprx) with a $27.00 price target. Cantor fitzgerald's charles duncan remains neutral on the stock. H.c. Wainwright has also reiterated a buy rating on the company. Catalyst pharma reported strong 3q revenues of $102.7m.
TipRanks · 11/10 14:38
Buy Rating for Catalyst Pharma Backed by Strong Performance and Optimistic Forecasts
TipRanks · 11/10 14:27
Sustained Growth and Strategic Inclusion: Key Factors Driving Catalyst Pharma’s Buy Rating
TipRanks · 11/10 11:54
Catalyst (CPRX) Q3 Earnings Miss, Sales Top, '23 View Up
NASDAQ · 11/09 13:16
More
About CPRX
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases. With the patient focus, the Company is engaged in developing a robust pipeline of cutting-edge, medicines for rare diseases. The Company's New Drug Application for FIRDAPSE (amifampridine) tablets 10 milligrams (mg) for the treatment of adults with Lambert-Eaton myasthenic syndrome (LEMS). The Company's FIRDAPSE is commercially available in the United States as a treatment for adults with LEMS. The Company also has FYCOMPA (perampanel) CIII, a prescription medicine approved in people with epilepsy aged four and older alone or with other medicines to treat partial-onset seizures with or without secondarily generalized seizures and with other medicines to treat primary generalized tonic-clonic seizures for people with epilepsy aged 12 and older.

Webull offers Catalyst Pharmaceuticals Inc stock information, including NASDAQ: CPRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CPRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CPRX stock methods without spending real money on the virtual paper trading platform.